Monitor for the completion of the PCAOB audit and regulatory approvals. The $12M gross-profit-minus-capex condition in each of FY2024 and FY2025 is a key go/no-go hurdle. If cleared, the stock should re-price to reflect the combined entity's new revenue and earnings scale. Also watch for any equity financing announcements despite the company's stated plan to avoid them.
Price Chart
Executive Summary
Aspire Biopharma ($8M market cap) signed a definitive agreement to acquire Dura Driver Control Systems (DCS), a global automotive tier-1 supplier with over $200M in FY2025 revenue and >$22M in Adjusted EBITDA, for $30M in cash. The transaction transforms Aspire from a pre-revenue biopharma into a diversified industrial enterprise, with DCS contributing 11 global manufacturing facilities, 310+ patents, and a blue-chip OEM customer base.
Key Financial Metrics
Key Facts
- Aspire to pay $30M cash to acquire 100% of Dura Driver Control Systems from FireFish TopCo (MiddleGround Capital)
- DCS generated over $200M in revenue and over $17M in net income for FY2025 (unaudited)
- DCS Adjusted EBITDA was over $22M for FY2025 (unaudited)
- Aspire states it does not anticipate any new equity financing to fund the deal
- Closing conditioned on PCAOB audit showing unqualified opinion and gross profit minus capex >= $12M in both FY2024 and FY2025
- Outside Date for closing is September 10, 2026; either party may terminate and collect a $3.5M termination fee under certain conditions
- DCS operates 11 global facilities across North America, Europe, and Asia, serving 50+ customers
Financial Impact
Acquisition of business with ~$200M+ annual revenue and ~$22M+ Adjusted EBITDA for $30M cash – a transformative revenue multiple for Aspire's current $8M market cap
Risk Factors
- Closing depends on PCAOB audit meeting $12M gross-profit-minus-capex threshold – failure gives Aspire termination right
- Integration risk from merging a pre-revenue biopharma into a global automotive manufacturer
- Potential undisclosed liabilities or IP issues from the pre-closing due diligence process
- $30M cash commitment is significant relative to Aspire's $8M market cap – balance sheet strain if execution falters
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028386 |
| Exhibit: ex99-1.htm | 0001493152-26-028386 |
| Document: form8-k.htm | 0001493152-26-028386 |
| Document: 0001493152-26-028386-index-headers.html | 0001493152-26-028386 |
| Document: 0001493152-26-028386-index.html | 0001493152-26-028386 |
| Document: 0001493152-26-028386.txt | 0001493152-26-028386 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K/A | $8.85 | awaiting T+20 | — | $8.44 (−4.63%) |
Aug 19, 2026 9w ago | 8-K | $7.90 $9.12 | ▲ +15.44% | ▲ +17.39% | $8.44 (+6.84%) |
Aug 10, 2026 11w ago | 8-K | $7.79 $8.85 | ▲ +13.61% | ▲ +14.52% | $8.44 (+8.34%) |
Jul 20, 2026 14w ago | 8-K | $7.54 $7.64 | ▲ +1.33% | ▼ −1.24% | $8.44 (+11.94%) |
Jun 12, 2026 19w ago | 8-K | $4.96 $6.01 | ▲ +21.17% | ▲ +19.39% | $8.44 (+70.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers